Article
Vaccines for the leishmaniases: proposals for a research agenda
Registration in:
The Working Group on Research Priorities for Development of Leishmaniasis Vaccines. Vaccines for the Leishmaniases: Proposals for a Research Agenda. PLoS Negl Trop Dis, v. 5, n.3, e943, 9p, Mar. 2011.
1935-2727
10.1371/journal.pntd.0000943
1935-2735
Author
The Working Group on Research Priorities for Development of Leishmaniasis Vaccines
Abstract
The members of the Working Group
on Research Priorities for Development
of Leishmaniasis Vaccines are: Nahid Ali,
Infectious Disease and Immunology Division,
Indian Institute of Chemical Biology, Kolkata,
India, nali@iicb.res.in; Eldo Cardoso de Brito,
Jr., Institute of Tropical Diseases Natan Portella,
Federal University of Piauı´, Teresina,
Brazil, eldocardoso@gmail.com; Cla´udia
Brodskyn, Research Center Gonc¸alo Moniz,
Fiocruz, Salvador, Brazil, brodskyn@cpqgm.
fiocruz.br; Antoˆnio Campos-Neto, The Forsyth
Institute, Boston, Massachusetts, United States
of America, acampos@forsyth.org; Edgar M.
Carvalho, Service of Immunology, University
Hospital Professor Edgard Santos, Federal
University of Bahia, Salvador, Brazil, edgar@
ufba.br; Kwang Poo Chang, Chicago Medical
School, Rosalind Franklin University, Chicago,
Illinois, United States of America, KwangPoo.
Chang@rosalindfranklin.edu; Carlos Henrique
Nery Costa, Institute of Tropical Diseases
Natan Portella, Federal University of Piauı´,
Teresina, Brazil, chncosta@gmail.com; Ana
Paula Fernandes, Department of Clinical and
Toxicological Analysis, School of Pharmacy,
Federal University of Minas Gerais, Belo
Horizonte, Brazil, anav@uai.com.br; Ricardo
Fujiwara, Laboratory of Immunology and
Genomics of Parasites, Department of Parasitology,
Biological Sciences Institute, Federal
University of Minas Gerais, Belo Horizonte,
Brazil, fujiwara@icb.ufmg.br; Ricardo Gazzinelli,
Rene´ Rachou Institute, Fiocruz, and
Department of Biochemistry and Immunology,
Biological Sciences Institute, Federal University
of Minas Gerais, Belo Horizonte, Brazil,
ritoga@cpqrr.fiocruz.br; Hiro Goto, Tropical
Diseases Institute of Sa˜o Paulo and School of
Medicine, University of Sa˜o Paulo (Instituto de
Medicina Tropical de Sa˜o Paulo e Faculdade de
Medicina, Universidade de Sa˜o Paulo), Sa˜o
Paulo, Brazil, hgoto@usp.br; Gabriel Grimaldi,
Laboratory of Research in Leishmaniasis,
Oswaldo Cruz Institute, Fiocruz, Rio de
Janeiro, Brazil, grimaldi@ioc.fiocruz.br; Paul
Kaye, Centre for Immunology and Infection, Hull York Medical School and Department of
Biology, University of York, York, United
Kingdom, pmk2@york.ac.uk; Lukasz Kedzierski,
The Walter and Eliza Hall Institute of
Medical Research, Parkville, Victoria, Australia,
kedzierski@wehi.edu.au; Ali Khamesipour,
Center for Research and Training in Skin
Diseases and Leprosy, Tehran University of
Medical Sciences, Tehran, Iran, khamesipour_
ali@yahoo.com; Carla Maia, Institute of Hygiene
and Tropical Medicine (Instituto de
Higiene e Medicina Tropical), Universidade
Nova de Lisboa, Lisbon, Portugal, carlamaia@
ihmt.unl.pt; Sandra Regina Maruyama, Department
of Biochemistry and Immunology,
Ribeira˜o Preto School of Medicine, University
of Sa˜o Paulo, Ribeira˜o Preto, Brazil,
sandrarcm@usp.br; W. Robert McMaster, Department
of Medical Genetics, University of
British Columbia, Vancouver, British Columbia,
Canada, robm@interchange.ubc.ca; Se´rgio
C. F. Mendonc¸a, Oswaldo Cruz Institute, Rio
de Janeiro, Brazil, mendonca@ioc.fiocruz.br;
Hira Lal Nakhasi, Division of Emerging and
Transfusion Transmitted Diseases, Office of
Blood Research and Review, Center for Biologics
Evaluation and Research, US Food and
Drug Administration, Bethesda, Maryland,
United States of America, hira.nakhasi@
fda.hhs.gov; Nathan C. Peters, Laboratory of
Parasitic Diseases, National Institute of Allergy
and Infectious Diseases, National Institutes of
Health, Bethesda, Maryland, United States of
America, NPeters@niaid.nih.gov; Franco Piazza,
Infectious Disease Research Institute, Seattle,
Washington, United States of America,
fpiazza@idri.org; Rupert Quinnell, Institute of
Integrative and Comparative Biology, University
of Leeds, Leeds, United Kingdom,
R.J.Quinnell@leeds.ac.uk; Alexandre Barbosa
Reis, Federal University of Ouro Preto and
Research Center Rene´ Rachou, Ouro Preto,
Brazil, alexreis@nupeb.ufop.br; Isabel K. Ferreira
de Miranda Santos, Department of
Biochemistry and Immunology, Ribeira˜o Preto
School of Medicine, University of Sa˜o Paulo,
Ribeira˜o Preto, Brazil, imsantos@fmrp.usp.br;
Gabriela Santos-Gomes, Hygiene and Tropical
Institute (Instituto de Higiene e Medicina
Tropical), New University of Lisbon, Lisbon,
Portugal, santosgomes@ihmt.unl.pt; Jeffrey
Shaw, Department of Parasitology, Institute of
Biomedical Research, University of Sa˜o Paulo,
Sa˜o Paulo, Brazil, jeffreyj@usp.br; Jesus Valenzuela,
Vector Molecular Biology Unit, Laboratory
of Malaria and Vector Research, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, Rockville, Maryland,
United States of America, jvalenzuela@
niaid.nih.gov; Peter Walden, Department of
Dermatology and Allergy, Charite´—Universita¨tsmedizin
Berlin, Humboldt University,
Berlin, Germany, peter.walden@charite.de;
Guilherme Werneck, National School of Public
Health Se´rgio Arouca, Fiocruz, Rio de Janeiro,
Brazil, gwerneck@ims.uerj.br. The International Symposium on Leishmaniasis
Vaccines, held in Olinda, Brazil,
on March 9–11, 2009, congregated international
experts who conduct research on
vaccines against the leishmaniases. The
questions that were raised during that
meeting and the ensuing discussions are
compiled in this report and may assist in
guiding a research agenda. A group to
further discussion on issues raised in this
policy platform has been set up at http://
groups.google.com/group/leishvaccines-l.